Summary of Baxter International Q2 2026 Earnings Call

1Key Financial Results and Metrics

Global Sales: Approximately $3 billion, up 5% on both reported and organic bases.

Adjusted Earnings: $0.56 per diluted share, a decrease from $0.59 in the prior year, impacted by known mechanical headwinds but partially offset by a $75 million tariff refund contributing approximately $0.11 per share.

Free Cash Flow: Positive at $181 million for the quarter, contributing to a year-to-date total of $257 million.

Adjusted Operating Margin: 14.2%, down 90 basis points due to higher manufacturing costs and unfavorable comparisons to the prior year.

2Strategic Updates and Business Highlights

Organic Revenue Growth: Driven by strong performance in Advanced Surgery and Drug Compounding, with all segments contributing positively.

Business Consolidation: The Pharmaceuticals business has been integrated into the Infusion Therapies & Technologies division, now called Infusion Therapies & Platforms (ITP), aimed at improving coordination and execution.

Innovation Initiatives: Launch of PeerVue, a digital benchmarking application, and the Vest APX Acute Care device, with positive early customer feedback.

Continuous Improvement: Over 400 continuous improvement events completed, with a focus on enhancing operational efficiency through the Baxter Growth & Performance System (GPS).

3Forward Guidance and Outlook

Full Year 2026 Sales Growth: Revised to 3% to 4% reported growth, with organic sales growth expected at 2% to 3%.

Adjusted EPS Guidance: Raised from $1.85-$2.05 to $1.95-$2.15 per diluted share, reflecting the impact of the tariff refund.

Margin Expectations: Continued expectation for adjusted operating margins to range between 13% to 14% for the year, with anticipated improvements in the second half due to higher volumes and cost structure benefits.

4Bad News, Challenges, or Points of Concern

Declining Adjusted Earnings: The decrease in adjusted earnings per share reflects ongoing headwinds, including the impact of higher cost inventory and unfavorable comparisons from the previous year.

Supply Chain Issues: Ongoing supply constraints in the injectable and anesthesia segments, particularly related to contract manufacturing, remain a concern.

Regulatory Challenges: The Novum IQ LVP infusion pump continues to face regulatory scrutiny, impacting sales and customer confidence.

Macroeconomic Uncertainty: Potential impacts from broader economic factors, including inflation and hospital capital spending, are being closely monitored.

5Notable Q&A Insights

Drivers of Q2 Performance: Management highlighted broad-based operational performance improvements, particularly in Drug Compounding and Advanced Surgery.

Tariff Refund Impact: The one-time tariff refund was a significant contributor to the earnings beat, but its nonrecurrence in future quarters raises questions about sustaining earnings growth.

Market Conditions: Despite stable demand, management acknowledged the need to monitor customer behavior closely due to potential impacts from healthcare policy changes.

Future Growth: While management expressed confidence in achieving growth in 2027, they emphasized the importance of executing well in the second half of 2026 to set a solid foundation. This summary encapsulates Baxter International's financial performance, strategic initiatives, and outlook while addressing challenges and insights from the Q&A session.